Market Place
Sourcing Support
iTeos Highlights Inupadenant Data For NSCLC At ESMO Congress
24 Oct 2024 //
GLOBENEWSWIRE
TIGITs Trend Upward After iTeos/GSK Present Positive Data at ESMO
07 Oct 2024 //
BIOSPACE
iTeos Reports Interim Analysis Of Belrestotug + Dostarlimab In NSCLC
14 Sep 2024 //
GLOBENEWSWIRE
iTeos to Participate in Upcoming Investor Conferences
28 Aug 2024 //
GLOBENEWSWIRE
iTeos To Present GALAXIES Lung-201 Data At ESMO Congress 2024
20 Aug 2024 //
GLOBENEWSWIRE
ITeos Reports Q2 2024 Financial Results And Business Updates
08 Aug 2024 //
GLOBENEWSWIRE
iTeos Therapeutics Names David Feltquate As Chief Medical Officer
05 Aug 2024 //
GLOBENEWSWIRE
iTeos Announces First Patient Dosed in GALAXIES Lung-301 Phase 3 Study
08 Jul 2024 //
GLOBENEWSWIRE
iTeos And GSK Initiate Phase 3 Study For Belrestotug And Dostarlimab In NSCLC
17 Jun 2024 //
GLOBENEWSWIRE
iTeos Therapeutics Announces $120 Million Registered Direct Offering
10 May 2024 //
GLOBENEWSWIRE
iTeos Reports First Quarter 2024 Financial Results and Provides Business Updates
10 May 2024 //
GLOBENEWSWIRE
iTeos to raise $120M; Xbrane and STADA to out-license Lucentis biosimilar
10 May 2024 //
ENDPTS
iTeos Presents EOS-984 Preclinical Data at the AACR
07 Apr 2024 //
GLOBENEWSWIRE
iTeos Reports Fourth Quarter and Full Year 2023 Financial Results
06 Mar 2024 //
GLOBENEWSWIRE
iTeos Appoints Oncology Veteran Jill DeSimone to Its Board of Directors
06 Mar 2024 //
GLOBENEWSWIRE
iTeos to Highlight Preclinical Data on First-In-Class EOS-984 Targeting ENT1
05 Mar 2024 //
GLOBENEWSWIRE
iTeos to Participate in Upcoming Investor Conferences
01 Mar 2024 //
GLOBENEWSWIRE
iTeos Announces 2024 Strategic Priorities and Anticipated Milestones
08 Jan 2024 //
GLOBENEWSWIRE
iTeos to Present at the 42nd Annual J.P. Morgan Healthcare Conference
03 Jan 2024 //
GLOBENEWSWIRE
iTeos to Present at the Piper Sandler 35th Annual Healthcare Conference
21 Nov 2023 //
GLOBENEWSWIRE
iTeos Reports Third Quarter 2023 Financial Results and Provides Business Updates
07 Nov 2023 //
GLOBENEWSWIRE
iTeos to Participate in Upcoming Investor Conferences
06 Sep 2023 //
GLOBENEWSWIRE
iTeos Reports Second Quarter 2023 Financial Results & Provides Business Updates
08 Aug 2023 //
GLOBENEWSWIRE
Arcus, Iteos Soar On Roche`s `Meaningful` Results In A New Cancer Drug Class
26 May 2023 //
INVESTOR
iTeos Reports First Quarter 2023 Financial Results and Provides Business Updates
10 May 2023 //
GLOBENEWSWIRE
iTeos Reports Fourth Quarter and Full Year 2022 Financial Results
15 Mar 2023 //
GLOBENEWSWIRE
iTeos to Present at Cowen 43rd Annual Health Care Conference
28 Feb 2023 //
GLOBENEWSWIRE
iTeos to Present at SVB Securities Global Biopharma Conference
07 Feb 2023 //
GLOBENEWSWIRE
iTeos Provides Business Updates and Clinical Development Plans for 2023
09 Jan 2023 //
GLOBENEWSWIRE
iTeos to Present at the 41st Annual J.P. Morgan Healthcare Conference
03 Jan 2023 //
GLOBENEWSWIRE
iTeos to Present at the Piper Sandler 34th Annual Healthcare Conference
22 Nov 2022 //
GLOBENEWSWIRE
iTeos Reports Third Quarter 2022 Financial Results and Provides Business Updates
10 Nov 2022 //
GLOBENEWSWIRE
Roche`s trial flop casts shadow on Big Pharma`s $6B TIGIT bet
17 May 2022 //
FIERCEBIOTECH
Roche`s TIGIT flop prompts GSK to evaluate next steps for rival
14 May 2022 //
FIERCEBIOTECH
iTeos Reports First Quarter 2022 Financial Results and Provides Business Update
12 May 2022 //
GLOBENEWSWIRE
iTeos Presents New Data for Anti-TIGIT Antibody, EOS-448/GSK4428859A, at AACR
08 Apr 2022 //
GLOBENEWSWIRE
iTeos Reports Fourth Quarter and Full Year 2021 Financial Results
23 Mar 2022 //
GLOBENEWSWIRE
iTeos to Present at the Cowen 42nd Annual Health Care Conference
01 Mar 2022 //
GLOBENEWSWIRE
iTeos to Participate in Upcoming Investor Conferences in February
10 Feb 2022 //
GLOBENEWSWIRE
iTeos Announces New Data for its Anti-TIGIT Antibody, EOS-448
09 Dec 2021 //
GLOBENEWSWIRE
iTeos reports results for the second quarter of 2021 and presents company update
13 Aug 2021 //
GLOBENEWS WIRE
Presentation of iTeos Therapeutics at the William Blair Biotech Conference 2021
09 Jul 2021 //
GLOBENEWSWIRE
iTeos Therapeutics to Present at William Blair Biotech Focus Conference 2021
08 Jul 2021 //
GLOBENEWSWIRE
iTeos busts out early human data for anti-TIGIT antibody. Is it enough to match
12 Apr 2021 //
ENDPTS
Annexon, Inozyme, iTeos snag $564M in upsized IPOs
25 Jul 2020 //
FIERCE BIOTECH
Phase 1/2 oncology biotech iTeos Therapeutics files for a $100 million IPO
25 Jun 2020 //
NASDAQ
iTeos Presents Preclinical Data for its Anti-TIGIT , EOS-448, at the AACR
22 Jun 2020 //
GLOBENEWSWIRE
iTeos Therapeutics to Present Preclinical Data for Anti-TIGIT antibody, EOS-448
15 Jun 2020 //
GLOBENEWSWIRE
iTeos Therapeutics Strengthens Leadership Team
08 Jun 2020 //
GLOBENEWSWIRE
iTeos`s Presents Data from First-in-Human Study of A2A Receptor Antagonist
27 Apr 2020 //
GLOBENEWSWIRE
iTeos Therapeutics to Present Data from First-in-Human Study of A2A Receptor
20 Apr 2020 //
GLOBENEWSWIRE
iTeos`s Initiates Phase 1/2 Study with Highly Innovative Anti-TIGIT Antibody
27 Feb 2020 //
PRESS RELEASE
iTeos Therapeutics Awarded €15 Million in Non-Dilutive Funding
30 Jan 2020 //
GLOBENEWSWIRE
iTeos Therapeutics Announces Collab with Merck Investigating the Combination
12 Dec 2019 //
GLOBENEWSWIRE
